Molecular Formula | C21H25ClO5S |
Molar Mass | 424.94 |
Density | 1.37±0.1 g/cm3(Predicted) |
Boling Point | 607.9±55.0 °C(Predicted) |
pKa | 12.87±0.70(Predicted) |
Storage Condition | -20℃ |
Use | LX-4211 are SGLT1/2 inhibitors and antidiabetic agents. |
In vitro study | LX4211 inhibits [14C]AMG uptake with IC50 of 62.0 nM and 0.6 nM for mouse SGLT1 and SGLT2, respectively. |
In vivo study | In mice, LX4211 (60 mg/kg, p.o.) decreased intestinal glucose absorption, by inhibiting SGLT1, resulted in a net increase in GLP-1 and PYY release and a decrease in GIP release and blood glucose excursion. In non-obese diabetes-prone mice with type I diabetes, Sotagliflozin (30 mg/kg) significantly improved glycemic control without increasing rates of hypoglycemia measurement. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.353 ml | 11.766 ml | 23.533 ml |
5 mM | 0.471 ml | 2.353 ml | 4.707 ml |
10 mM | 0.235 ml | 1.177 ml | 2.353 ml |
5 mM | 0.047 ml | 0.235 ml | 0.471 ml |